REMS review explores programs' burdens.
Kate
K
Traynor
D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015474:Isotretinoin / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment / Q000379:methods*; D014481:United States; D014486:United States Food and Drug Administration
D003879:Dermatologic Agents; D015474:Isotretinoin